当前位置: 首页 >> 检索结果
1021. A randomized controlled trial on the effect of inhaled corticosteroids on airways inflammation in adult cigarette smokers.
作者: G Cox.;L Whitehead.;M Dolovich.;M Jordana.;J Gauldie.;M T Newhouse.
来源: Chest. 1999年115卷5期1271-7页
To determine whether inhaled corticosteroid treatment can reduce airways inflammation in adult cigarette smokers.
1022. Utility of transbronchial needle aspiration in the diagnosis of endobronchial lesions.
作者: A Dasgupta.;P Jain.;O A Minai.;S Sandur.;Y Meli.;A C Arroliga.;A C Mehta.
来源: Chest. 1999年115卷5期1237-41页
The utility of transbronchial needle aspiration (TBNA) in visible endobronchial lesions presenting as either an exophytic mass lesion (EML) or submucosal and peribronchial disease (SPD) is not well established.
1023. Effect of betaxolol on the hemodynamic, gas exchange, and cardiac output response to exercise in chronic atrial fibrillation.
作者: J E Atwood.;J Myers.;S Quaglietti.;J Grumet.;R Gianrossi.;T Umman.
来源: Chest. 1999年115卷4期1175-80页
beta-blockade controls the ventricular response to exercise in chronic atrial fibrillation (AF), but the effects of beta-blockers on exercise capacity in AF have been debated.
1024. The unidirectional valve is the best method to determine maximal inspiratory pressure during weaning.
Although maximal inspiratory pressure (MIP) is used as an index of inspiratory muscular strength, there is no consensus on how to measure it. We compared, during weaning from mechanical ventilation, two methods of measurement to determine which shows the greater values (MIPbest) and is more reproducible. One method measured MIP when negative pressure was maintained for at least 1 s after a forceful expiration, and the other method measured MIP with a unidirectional expiratory valve (MIPuni).
1025. The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD.
作者: P M Dorinsky.;C Reisner.;G T Ferguson.;S S Menjoge.;C W Serby.;T J Witek.
来源: Chest. 1999年115卷4期966-71页
To determine whether the combination of ipratropium bromide and albuterol results in greater and more consistent pulmonary function test (PFT) response rates than ipratropium bromide or albuterol alone in patients with COPD.
1026. Efficacy of salmeterol xinafoate in the treatment of COPD.
作者: D A Mahler.;J F Donohue.;R A Barbee.;M D Goldman.;N J Gross.;M E Wisniewski.;S W Yancey.;B A Zakes.;K A Rickard.;W H Anderson.
来源: Chest. 1999年115卷4期957-65页
To examine and compare the efficacy and safety of salmeterol xinafoate, a long-acting inhaled beta2-adrenergic agonist, with inhaled ipratropium bromide and inhaled placebo in patients with COPD.
1027. Clickhaler (a novel dry powder inhaler) provides similar bronchodilation to pressurized metered-dose inhaler, even at low flow rates.
Comparison of the bronchodilator response to an albuterol novel dry powder inhaler (DPI) (Clickhaler [CH]; ML Laboratories PLC; St. Albans, UK) activated at various inspiratory flow rates and to an albuterol pressurized metered-dose inhaler (pMDI) by patients with moderate to moderately severe stable asthma.
1028. Safety of long-term treatment with HFA albuterol.
Chlorofluorocarbons (CFCs) used as propellants in metered-dose inhalers deplete stratospheric ozone, which results in serious public health concerns. Albuterol has been reformulated in the non-ozone-depleting propellant, hydrofluoroalkane-134a (HFA albuterol).
1029. Effect of continuously nebulized ipratropium bromide plus albuterol on emergency department length of stay and hospital admission rates in patients with acute bronchospasm. A randomized, controlled trial.
To compare the outcome of patients with acute bronchospasm treated with continuously nebulized albuterol plus ipratropium bromide vs albuterol alone.
1030. Positional treatment vs continuous positive airway pressure in patients with positional obstructive sleep apnea syndrome.
The aim of this study was to compare the relative efficacy of continuous positive airway pressure (CPAP) and positional treatment in the management of positional obstructive sleep apnea (OSA), using objective outcome measures.
1031. Site of pleural drain insertion and early postoperative pulmonary function following coronary artery bypass grafting with internal mammary artery.
Coronary artery bypass graft (CABG) surgery using the left internal mammary artery (LIMA) impairs postoperative pulmonary function. We studied the changes in pulmonary function and subjective pain relative to the site of chest tube insertion.
1032. Nocturnal asthma: effect of salmeterol on quality of life and clinical outcomes.
作者: R F Lockey.;L M DuBuske.;B Friedman.;V Petrocella.;F Cox.;K Rickard.
来源: Chest. 1999年115卷3期666-73页
To evaluate the effect of salmeterol on asthma-specific quality of life in patients experiencing significant nocturnal symptoms.
1033. Long-term cardiovascular safety of salmeterol powder pharmacotherapy in adolescent and adult patients with chronic persistent asthma: a randomized clinical trial.
作者: P Chervinsky.;P Goldberg.;S Galant.;Y Wang.;T Arledge.;M B Welch.;E Stahl.
来源: Chest. 1999年115卷3期642-8页
This study investigates the long-term cardiovascular safety of salmeterol powder vs placebo in adolescent and adult patients with mild persistent asthma.
1034. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD.
作者: M Friedman.;C W Serby.;S S Menjoge.;J D Wilson.;D E Hilleman.;T J Witek.
来源: Chest. 1999年115卷3期635-41页
To conduct a post hoc pharmacoeconomic evaluation of two double-blind, randomized, prospective, parallel group studies comparing the long-term efficacy and safety of ipratropium combined with albuterol in a single inhalational canister against either bronchodilator agent alone in patients with COPD.
1035. Inhaled beclomethasone dipropionate reverts tolerance to the protective effect of salmeterol on allergen challenge.
作者: D Giannini.;E Bacci.;F L Dente.;A Di Franco.;B Vagaggini.;R Testi.;P Paggiaro.
来源: Chest. 1999年115卷3期629-34页
One week of regular treatment with salmeterol can induce tolerance to the protective effect of a beta2-agonist on early airway response to allergen (EAR). The objective was to assess whether inhaled corticosteroids revert tolerance to salmeterol.
1036. A bolus of inhaled budesonide rapidly reverses airway subsensitivity and beta2-adrenoceptor down-regulation after regular inhaled formoterol.
Subsensitivity of airway beta2-adrenoceptors develops readily in asthmatics receiving regular long-acting beta2-agonists. This subsensitivity may be rapidly reversed by using systemic corticosteroids. The purpose of the present study was to investigate whether the same acute facilitatory effects occur when using a bolus dose of inhaled corticosteroid.
1037. Salbutamol metered-dose inhaler with spacer for hyperkalemia: how fast? How safe?
作者: A Mandelberg.;Z Krupnik.;S Houri.;S Smetana.;E Gilad.;Z Matas.;I E Priel.
来源: Chest. 1999年115卷3期617-22页
To determine the efficacy of inhaled salbutamol (rapidly delivered, using a metered-dose inhaler with a spacer device [MDI-S]) in lowering the serum potassium levels in patients with hyperkalemia.
1038. A randomized and controlled trial of the effect of treatment aimed at maximizing oxygen delivery in patients with severe sepsis or septic shock.
作者: I Alía.;A Esteban.;F Gordo.;J A Lorente.;C Diaz.;J A Rodriguez.;F Frutos.
来源: Chest. 1999年115卷2期453-61页
To evaluate the effects of increased oxygen delivery on mortality and morbidity.
1039. Effect of infused angiotensin II on the bronchoconstrictor activity of inhaled endothelin-1 in asthma.
Endothelin (ET)-1 is a potent bronchoconstrictor, and asthmatics demonstrate bronchial hyperresponsiveness to ET-1 given by inhalation. Angiotensin II (Ang II) is increased in plasma in acute severe asthma, causes bronchoconstriction in asthmatics, and potentiates contractions induced by ET-1 in bovine bronchial smooth muscle in vitro, and contractions induced by methacholine both in vitro and in vivo. We wished to examine any potentiation of the bronchoconstrictor activity of inhaled ET-1 by infused Ang II at subbronchoconstrictor doses.
1040. Hydrofluoroalkane-134a beclomethasone dipropionate, 400 microg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 microg, for the treatment of moderate asthma.
The improved lung deposition of hydrofluoroalkane-134a beclomethasone dipropionate (HFA-BDP) extrafine aerosol compared with chlorofluorocarbon beclomethasone dipropionate (CFC-BDP) suggests that lower doses of HFA-BDP may be required to provide equivalent asthma control. The present study was undertaken to test this hypothesis.
|